Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of “Buy” by Brokerages


Share on StockTwits

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have earned an average rating of “Buy” from the fourteen brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $44.83.

A number of equities research analysts recently issued reports on HALO shares. Zacks Investment Research cut shares of Halozyme Therapeutics from a “hold” rating to a “sell” rating and set a $46.00 price objective for the company. in a report on Tuesday, March 16th. Benchmark upped their price target on shares of Halozyme Therapeutics from $46.00 to $59.00 and gave the company a “buy” rating in a report on Thursday, January 21st. Berenberg Bank started coverage on shares of Halozyme Therapeutics in a report on Thursday, December 17th. They set a “buy” rating and a $50.00 price target for the company. BMO Capital Markets upped their price target on shares of Halozyme Therapeutics from $56.00 to $65.00 and gave the company an “outperform” rating in a report on Monday, January 25th. Finally, Piper Sandler upped their price target on shares of Halozyme Therapeutics from $42.00 to $50.00 and gave the company an “overweight” rating in a report on Thursday, January 14th.

NASDAQ:HALO traded up $1.47 during trading hours on Friday, reaching $45.95. The company’s stock had a trading volume of 1,362,112 shares, compared to its average volume of 1,405,738. The company has a market cap of $6.58 billion, a price-to-earnings ratio of 287.19 and a beta of 1.77. Halozyme Therapeutics has a one year low of $17.74 and a one year high of $56.40. The business’s 50-day moving average is $43.20 and its 200-day moving average is $40.59. The company has a debt-to-equity ratio of 3.98, a current ratio of 18.49 and a quick ratio of 16.36.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 23rd. The biopharmaceutical company reported $0.50 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.56 by ($0.06). The business had revenue of $121.70 million during the quarter, compared to the consensus estimate of $120.75 million. Halozyme Therapeutics had a return on equity of 24.29% and a net margin of 10.78%. The company’s revenue for the quarter was up 126.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.24) earnings per share. On average, sell-side analysts predict that Halozyme Therapeutics will post 0.95 EPS for the current fiscal year.

In related news, SVP Michael J. Labarre sold 18,324 shares of the stock in a transaction dated Monday, March 1st. The shares were sold at an average price of $45.81, for a total value of $839,422.44. Following the completion of the sale, the senior vice president now owns 129,330 shares in the company, valued at $5,924,607.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kenneth J. Kelley sold 5,000 shares of the stock in a transaction dated Wednesday, April 14th. The stock was sold at an average price of $45.00, for a total transaction of $225,000.00. Following the completion of the transaction, the director now directly owns 179,833 shares of the company’s stock, valued at approximately $8,092,485. The disclosure for this sale can be found here. In the last quarter, insiders sold 212,013 shares of company stock valued at $9,581,726. 2.60% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. Veriti Management LLC raised its position in Halozyme Therapeutics by 6.5% in the first quarter. Veriti Management LLC now owns 5,030 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 308 shares in the last quarter. Louisiana State Employees Retirement System raised its position in Halozyme Therapeutics by 3.8% in the first quarter. Louisiana State Employees Retirement System now owns 33,000 shares of the biopharmaceutical company’s stock worth $1,376,000 after purchasing an additional 1,200 shares in the last quarter. EFG Asset Management Americas Corp. raised its position in Halozyme Therapeutics by 22.6% in the first quarter. EFG Asset Management Americas Corp. now owns 8,388 shares of the biopharmaceutical company’s stock worth $350,000 after purchasing an additional 1,545 shares in the last quarter. Scout Investments Inc. raised its position in Halozyme Therapeutics by 11.3% in the first quarter. Scout Investments Inc. now owns 336,754 shares of the biopharmaceutical company’s stock worth $14,039,000 after purchasing an additional 34,251 shares in the last quarter. Finally, Pacer Advisors Inc. raised its position in Halozyme Therapeutics by 36.0% in the first quarter. Pacer Advisors Inc. now owns 15,743 shares of the biopharmaceutical company’s stock worth $656,000 after purchasing an additional 4,165 shares in the last quarter. 98.45% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Story: How are capital gains distributions different for tax-deferred account?

Analyst Recommendations for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.